🚨 JD VANCE SENDS HHS GENDER-CARE BILLING REPORT TO DOJ — SAYS DELIBERATE INSURANCE FRAUD SHOULD LAND PEOPLE BEHIND BARS
Vice President JD Vance has formally placed a new Department of Health and Human Services report on pediatric gender-related medical billing in the hands of Attorney General Todd Blanche, asking the Justice Department to determine whether hospitals, clinics or other providers violated federal law.
Vance’s message was deliberately blunt. If providers intentionally used inaccurate diagnosis codes to obtain Medicaid or private-insurance payments for treatments that otherwise would not have been covered, he wrote, they should face criminal accountability — including prison where the evidence supports fraud charges.
The referral is real. So are the unusual billing patterns identified by HHS. But the most important legal distinction is equally real: the report does not establish that the roughly $50 million, $11 million or $120 million figures it discusses are proven fraud.
HHS itself says key parts of its nationwide claims analysis are “directional signals rather than findings” and require verification against underlying medical and billing records.
A suspicious billing pattern can justify an investigation. It is not the same as proof that a doctor or hospital knowingly committed insurance fraud.
Vance Referred the Report Directly to the Attorney General
The August 13 referral followed HHS’s release of a 64-page commissioned report titled “Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of ‘Gender Medicine.’”
Vance, acting as chairman of the White House Task Force to Eliminate Fraud, asked Blanche and the Justice Department to review the report and determine whether providers identified in the underlying analysis violated federal laws, regulations or policies.
His letter specifically focused on the possibility that providers may have used diagnostic coding to obtain insurance coverage for puberty blockers, cross-sex hormones or other gender-related interventions.
Vance wrote that providers who deliberately miscode treatment in order to obtain reimbursement should be held accountable. He then added the line that has driven most of the political attention: if the miscoding was intentional and amounted to fraud against Medicaid or private insurers, “they should go to prison.”
HHS Secretary Robert F. Kennedy Jr. separately referred a defined set of claims to the HHS Office of Inspector General for review.
Vance asked DOJ to investigate and determine whether federal law was violated. He did not announce indictments, convictions or a DOJ finding that the listed providers committed crimes.
The Report Says More Than 225 Health Systems Established Pediatric Gender Programs
HHS says more than 225 hospitals and health systems established pediatric gender programs nationwide as the field expanded during the 2010s and early 2020s.
The report argues that the growth of those programs created financial incentives for hospitals because patients receiving puberty blockers, hormones or surgery can require recurring specialist care, laboratory testing and follow-up treatment.
That is one of the report’s central theories, but the document is not a neutral actuarial audit. It was commissioned by HHS and includes contributors affiliated with organizations that have publicly opposed pediatric gender-transition medicine, including the Center for Christian Virtue, Independent Women’s Forum and the Ethics and Public Policy Center.
The report also uses explicitly adversarial language to describe the medical field it is examining.
Those facts do not invalidate the claims data. They do mean that statistical findings and causal conclusions should be separated carefully from the report’s political and medical arguments.
The existence of more than 225 pediatric gender programs is not evidence that all — or even most — of those institutions engaged in fraudulent billing.
The $50 Million Figure Is a Billing Signal, Not a Fraud Judgment
The strongest numerical finding in HHS’s own nationwide claims analysis involves puberty-blocking drugs billed between 2015 and 2025.
HHS identified nearly $50 million in billed charges for patients ages 9 through 17 where a puberty blocker appeared on the same claim as an endocrine-disorder diagnosis, while the same claim did not include a gender-related diagnosis or a central-precocious-puberty diagnosis.
The report focuses particularly on ICD-10 code E34.9, “endocrine disorder, unspecified.” HHS argues that using an endocrine code as a substitute for a gender-dysphoria diagnosis could improperly influence whether an insurer pays the claim.
That is a legitimate fraud question if the diagnosis was knowingly false.
But claims data alone generally cannot establish why a clinician selected a code, what documentation existed in the medical record, whether multiple diagnoses were submitted on separate claims, whether the payer requested a particular coding structure or whether an error was intentional.
HHS acknowledges those limitations. The report notes that patient ages were estimated from birth year, that billed-charge data can be incomplete and that the results require verification against the source records.
The approximately $50 million represents claims HHS flagged for review. It should not be described as $50 million in proven fraudulent payments.
The 4.7% Statistic Comes From One Academic Medical Center — and Needs Context
Vance highlighted a striking statistic from the report: that only about 4.7 percent of patients coded with “endocrine disorder, unspecified” had what HHS characterized as an actual non-gender-related endocrine condition.
The underlying source was a 2023 peer-reviewed study from an academic medical center examining how electronic health records could identify gender-expansive patients.
That study found that E34.9 appeared in 1,480 patients. Of those patients, 1,408 — about 95 percent — were identified by chart review as gender-expansive, while 71 were cisgender patients whose E34.9 code documented an endocrine condition unrelated to gender dysphoria.
HHS interprets that pattern as evidence that the unspecified endocrine code was frequently being used as a proxy for gender-related care.
That is a noteworthy coding pattern. But it is evidence from one health system and was originally studied for the purpose of identifying gender-expansive patients in electronic records, not as a nationwide criminal-fraud audit.
The 4.7% figure supports scrutiny of how E34.9 was being used at one academic medical center; it does not prove that 95% of E34.9 claims nationwide were fraudulent.
The Report’s 30% Increase Is Not a New Peer-Reviewed National Study
Vance also cited a roughly 30 percent increase in E34.9 diagnoses among minors.
The HHS report traces that number to a Manhattan Institute claims analysis discussed in a 2025 City Journal article, not to a new nationwide peer-reviewed clinical study commissioned by the government.
The report’s authors argue that a sudden increase in unspecified endocrine diagnoses is difficult to explain through a comparable increase in underlying endocrine disease and may instead reflect more frequent use of the code for gender-related treatment.
That hypothesis can be tested by examining individual records and billing histories.
Standing alone, however, a rise in the use of a billing code cannot establish criminal intent.
A statistical increase can identify an anomaly. Fraud requires evidence that a provider knowingly or intentionally submitted false information to obtain payment.
HHS Also Flagged Nearly $11 Million in Precocious-Puberty Claims for Ages 13 to 17
A second HHS cohort focused on puberty blockers billed with a central precocious puberty diagnosis for patients ages 13 through 17.
The report says nearly $11 million in billed charges appeared in this category between 2015 and 2025 and argues that the age range is suspicious because central precocious puberty is defined by unusually early pubertal onset — traditionally before age 8 in girls and age 9 in boys.
That makes a new diagnosis beginning in the teenage years an obvious question for auditors.
But age alone still does not establish fraud. Current Endocrine Society guidance says treatment for genuine central precocious puberty is usually not continued beyond roughly ages 10 to 11 in girls or 11 to 12 in boys, while also recognizing that individualized clinical reasons can justify treatment beyond those ages.
A 13- to 17-year-old claim could therefore warrant detailed review without automatically proving that the original diagnosis was fabricated.
A precocious-puberty code on an older teenager’s claim is unusual and may justify investigation, but the code alone cannot show whether the patient had a genuine earlier diagnosis or whether the billing was intentionally false.
The Nearly $120 Million Figure Comes From an Outside Watchdog Database
The report also cites almost $120 million in nationwide hospital and clinic billings since 2019, encompassing more than 5,500 surgical procedures and more than 8,500 courses of hormones or puberty blockers involving minors.
That figure is not generated by the same HHS claims analysis that produced the $50 million and $11 million cohorts.
The report cites the Stop the Harm Database, a project associated with the advocacy organization Do No Harm, for approximately $119.8 million in total submitted charges.
Submitted charges are also not the same thing as insurer payments or hospital profit. Hospitals may bill an amount significantly different from what an insurer ultimately allows or pays.
The number can illustrate the financial scale of the care being examined, but it should not be relabeled as $120 million stolen from taxpayers or insurers.
Nearly $120 million refers to reported submitted charges in an outside watchdog database. It is not a federal finding that providers collected $120 million through fraud.
The Cost Argument Is About Lifetime Treatment, Not $75,000 a Year
HHS compares the cost of ordinary pediatric healthcare with the potential long-term cost of gender-related medical treatment.
The report cites average annual healthcare spending for a child at roughly $3,000.
It then cites estimates that lifetime medical spending associated with hormone treatment can reach roughly $25,000 to $75,000 without surgery, while combinations of surgical interventions can push costs toward $170,000.
Those figures are presented by HHS as evidence of a financial incentive for healthcare systems to develop long-term treatment programs.
But the timeframes are critical. The $3,000 figure is annual pediatric spending, while the $25,000 to $75,000 estimate is a lifetime treatment figure, and the approximately $170,000 figure combines multiple surgical costs.
Comparing them without that distinction makes the financial difference appear far larger than the cited sources actually show.
The report does not show that the typical minor generates $75,000 or $170,000 in annual revenue for a hospital.
Kennedy’s Inspector General Referral Is More Targeted Than the Headline Suggests
Kennedy’s referral to the HHS Inspector General identifies specific categories of claims that the department wants audited.
Those include puberty-blocker claims paired with endocrine-disorder coding but without gender-related or precocious-puberty diagnoses; puberty-blocker claims using precocious-puberty coding for patients ages 13 through 17; and certain same-day hormone prescriptions associated with a primary gender-dysphoria diagnosis in states where treatment restrictions were in force.
The appendix to the HHS report lists organizations that appear in the relevant data cohorts.
The report itself warns that being listed does not indicate claim volume and that some organization names may appear under multiple National Provider Identifier records.
For the hormone cohort, HHS expressly states that further investigation is required to determine potential wrongdoing.
Appearing in an HHS referral list means an organization’s claims matched a screening criterion. It does not mean HHS has established that the organization committed fraud.
Federal Fraud Law Would Require More Than a Coding Disagreement
The report identifies several potential federal statutes that investigators could examine, including the False Claims Act and the federal health-care fraud statute.
Those laws can carry major financial penalties and, in criminal cases, prison sentences.
But criminal health-care fraud requires proof beyond a coding dispute. Prosecutors generally must establish knowing and willful conduct designed to defraud a health-care benefit program or obtain money through materially false representations.
A coding error, ambiguity, disagreement about medical necessity or administrative mistake is not automatically a federal crime.
That is why Vance’s own formulation is important: he called for prison if providers intentionally miscoded treatment and thereby perpetrated fraud.
Intent is not a technicality. It is a central difference between suspicious billing, recoverable overpayments, civil liability and a criminal fraud conviction.
DOJ Was Already Investigating Pediatric Gender-Care Providers Before This Referral
The new HHS referral does not arrive in a vacuum.
The Justice Department has already described an ongoing national investigation into possible federal-law violations connected with pediatric gender-related medical treatment.
Before the HHS report was released, DOJ announced agreements with several major medical institutions, including Cleveland Clinic and Connecticut Children’s, under which the institutions agreed to stop providing certain treatments to minors and accepted other conditions.
Those Justice Department announcements expressly stated that the government’s underlying claims were allegations and that there had been no determination of liability in the cited resolutions.
The new billing referral could feed into that broader federal enforcement effort, but DOJ has not publicly announced new criminal indictments based specifically on the August 13 HHS report.
Existing DOJ investigations and civil resolutions do not prove the separate billing allegations in the new HHS report.
The Medicaid and CHIP Rule Is Final — but It Is Not Yet in Effect
The referral also followed a separate administration action restricting federal funding for pediatric gender-related procedures.
CMS finalized a rule prohibiting federal Medicaid funding for covered procedures for individuals under 18 and federal CHIP funding for individuals under 19.
The rule includes a transition period of up to six months for certain beneficiaries already receiving hormone therapy.
The most important timing detail is that the regulation does not take effect until October 13, 2026.
That means articles saying federal Medicaid and CHIP funding has already ended everywhere overstate the present legal effect of the rule.
The Medicaid and CHIP funding restriction has been finalized, but its effective date is October 13, 2026.
Hospitals Have Not Been Convicted by the Release of a Government Report
The political language surrounding the HHS report is unusually severe, and the administration is openly arguing that children were harmed and taxpayers may have been defrauded.
Healthcare organizations and supporters of gender-affirming care dispute the administration’s broader characterization of the field and argue that appropriately selected treatment can be medically beneficial for some transgender adolescents.
Reuters reported that the American Hospital Association declined to comment on the report and that Boston Children’s Hospital said it was reviewing the findings.
The strongest way to test the government’s billing allegations is therefore the same process Vance has now requested: obtain the underlying records, determine what diagnoses patients actually had, identify what insurers were told and establish whether any inaccurate coding was deliberate.
What Can Actually Be Said With Confidence
The strongest defensible conclusion is that the Trump administration has moved from political criticism of pediatric gender medicine into a more specific federal fraud-enforcement phase.
HHS has published a commissioned report identifying billing patterns it considers potentially improper.
The department’s nationwide claims analysis found nearly $50 million in puberty-blocker charges paired with endocrine-disorder diagnoses under defined screening criteria, and nearly $11 million in puberty-blocker charges paired with precocious-puberty diagnoses for patients ages 13 through 17.
The report also cites an outside watchdog database reporting nearly $120 million in submitted charges involving more than 5,500 surgeries and more than 8,500 hormone or puberty-blocker treatment courses for minors.
Vice President JD Vance has referred the report to Attorney General Todd Blanche. HHS Secretary Robert F. Kennedy Jr. has referred selected claim cohorts to the HHS Inspector General.
Vance has said that if investigators prove providers intentionally miscoded treatment to defraud Medicaid or private insurers, they should go to prison.
What has not happened is equally important.
The $50 million, $11 million and $120 million figures have not been adjudicated as fraud losses. The HHS report expressly describes important portions of its claims analysis as directional signals requiring verification. Being named in a data cohort is not a conviction, and DOJ has not publicly announced criminal charges based specifically on this referral.
The next stage is therefore the one that determines whether the headline becomes a criminal case: investigators must move from claims data to patient records, coding documentation, insurer rules and evidence of intent.
May you like
If that evidence proves deliberate deception, federal fraud law provides serious consequences.
If it does not, an alarming billing pattern remains an allegation rather than a crime.
